Merck to help make Johnson & Johnson's COVID-19 vaccine: White House official
Reuters
Published Mar 02, 2021 10:29AM ET
Updated Mar 02, 2021 03:20PM ET
By Michael Erman and Nandita Bose
Merck & Co Inc will help make rival Johnson & Johnson (NYSE:JNJ)'s single-shot COVID-19 vaccine in a partnership set to be announced on Tuesday by U.S. President Joe Biden, White House press secretary Jen Psaki said.
J&J's vaccine production has been slower than promised, and the Biden administration pushed the deal to try to improve output.
"As soon as we learned about the fact that Johnson and Johnson was behind in the manufacturing steps and efforts, we took steps to ensure we can expedite that and partner them with one of the world's biggest manufacturers," Psaki told a White House briefing.
Psaki said the U.S. government will invoke the Defense Production Act in order to equip Merck's plants to be able to produce the J&J vaccine.
She said Biden should provide more detail later on Tuesday. He is scheduled to speak on COVID-19 at 4:15 p.m. (2115 GMT)
More doses sooner could speed the U.S. vaccination effort considerably, because as a one-dose vaccine it is possible to inoculate twice as many people with the same number of shots. The other two U.S.-approved vaccines - from Pfizer Inc (NYSE:PFE) and BioNTech and Moderna (NASDAQ:MRNA) Inc - require two doses.
Under its contract, J&J was supposed to deliver 12 million doses by the end of February, but had less than 4 million ready to ship when the vaccine was authorized on Saturday.
It expects to be able to deliver another 16 million doses by the end of the month - still well short of its previous commitments - but will not ship any next week. The company has said it will be able to provide the full 100 million doses it has agreed to supply by its original midyear deadline.
The next shipments are waiting on regulatory approval of new manufacturing operations run by its partner, contract drugmaker Catalent (NYSE:CTLT) Inc, J&J Chief Scientific Officer Paul Stoffels said in an interview on Monday.
J&J did not immediately respond to a request for comment on the Merck arrangement.
Merck's collaboration with J&J comes after Merck scrapped development of its own COVID-19 vaccine candidates in January, Merck last month said it was working on a deal to open up its manufacturing capacity to other vaccine makers.
The partnership is the latest example of large drugmakers working together to help produce COVID-19 vaccines to meet the global demand.
Get The News You Want
Swiss drugmaker Novartis signed an agreement in January to fill vials for Pfizer and BioNTech's shot, while French drugmaker Sanofi (NASDAQ:SNY) SA will help fill and pack millions of doses of Pfizer's vaccine starting in July.
Merck will dedicate two U.S. facilities to J&J's vaccine, according to a report in the Washington Post, which first reported the news of the arrangement on Tuesday. (https://wapo.st/304E8ZQ)
"Merck remains steadfast in our commitment to contribute to the global response to the pandemic," the company said.
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.